ENTA
Enanta Pharmaceuticals, Inc.
ENTA trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over ENTA overall, supported by stronger fundamentals and stronger modeled upside.
ENTA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
ENTA's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ENTA PE Valuation
ENTA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ENTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect ENTA's losses to shrink, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ENTA on the outlook, with more favorable revenue expectations.
ENTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.42 | +$1.90 |
| Q1 2026 | -$2.60 | +$1.94 |
| Q4 2025 | -$3.21 | +$1.74 |
| Q3 2025 | -$3.84 | +$1.64 |
| Q2 2025 | -$4.32 | +$1.14 |
| Q1 2025 | -$4.54 | +$1.71 |
| Q4 2024 | -$4.95 | +$1.62 |
| Q3 2024 | -$5.48 | +$0.90 |
ENTA is still losing money, but far less than before: $2.42 per share over the past year, against $6.57 at its worst in late 2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ENTA on earnings quality, reporting a profit while its opponent remains loss making.
ENTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $14.4M | -22% |
| Q1 2026 | $17.2M | +15% |
| Q4 2025 | $18.6M | +9.8% |
| Q3 2025 | $15.1M | +3.5% |
| Q2 2025 | $18.3M | +1.9% |
| Q1 2025 | $14.9M | -12% |
| Q4 2024 | $17M | -5.8% |
| Q3 2024 | $14.6M | -23% |
ENTA's revenue fell from its 2019 peak and has held roughly level since: $14M last quarter, down 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -120% | -17 points |
| Q1 2026 | -69% | +95 points |
| Q4 2025 | -60% | +78 points |
| Q3 2025 | -122% | +83 points |
| Q2 2025 | -103% | +31 points |
| Q1 2025 | -164% | +28 points |
| Q4 2024 | -139% | +55 points |
| Q3 2024 | -204% | -41 points |
ENTA's operating margin was −120% last quarter, down 17 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ENTA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ENTA on profitability, with a higher operating margin.
ENTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10M | -158% |
| Q1 2026 | -$7.2M | +$8.9M |
| Q4 2025 | -$11.8M | +$13.7M |
| Q3 2025 | -$7.9M | +$11.4M |
| Q2 2025 | $17.4M | +$38.7M |
| Q1 2025 | -$16M | +$14.2M |
| Q4 2024 | -$25.5M | +$229K |
| Q3 2024 | -$19.4M | +$3.6M |
ENTA has burned cash in almost every quarter: −$37M over the past year, against −$44M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ENTA on cash generation, producing positive trailing cash flow while its opponent burns cash.
ENTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +50K shares |
| 1 year | +36% | +7.7M shares |
| 3 years | +40% | +8.4M shares |
| 5 years | +45% | +9.1M shares |
ENTA has 29M diluted shares, up 36% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ENTA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ENTA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2020 | -5.0x | Net Cash |
| Q4 2019 | -1.1x | Net Cash |
| Q3 2019 | -1.3x | Net Cash |
ENTA has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ENTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.1 | Neutral |
| Stochastic | 14.2 | Oversold |
ENTA's weekly RSI is 43 (neutral) and its Stochastic is 14 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ENTA PE vs Healthcare Sector
| Metric | ENTA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ENTA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ENTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.6 | 3.6% below |
| 20 week MA | $12.7 | 12% below |
| 50 week MA | $13.3 | 15% below |
| 100 week MA | $10.4 | 7.8% above |
| 200 week MA | $14.5 | 23% below |
ENTA's trend is mixed: it's above one of its five weekly moving averages, and 23% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ENTA on trend strength, trading above more of its moving averages.
ENTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.5 | $42.9 | -31% |
| 2021 | $42.9 | $76.4 | +78% |
| 2022 | $76.4 | $47.1 | -38% |
| 2023 | $47.1 | $9.41 | -80% |
| 2024 | $9.41 | $6.01 | -36% |
| 2025 | $6.01 | $16.9 | +180% |
| 2026 YTD | $16.9 | $11.2 | -34% |
ENTA's yearly returns have swung widely, from +180% in 2025 to −80% in 2023. It's down 34% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ENTA on returns for 2026, with the stronger performance.